- Recommended early peanut introduction for low-risk infants (no or mild/moderate eczema and no egg allergy).
- Ordered a peanut-specific immunoglobulin E test, provided counseling, or referred to an allergist for high-risk infants (severe eczema and/or egg allergy).
Key findings
The results demonstrated a significant improvement in adherence among intervention practices:
- Low-risk infants: 83.7% adherence in intervention vs 34.7% in control (OR 14.6; 95% CI, 7.0–30.5; P < .001).
- High-risk infants: 26.8% adherence in intervention vs 10.4% in control (OR 3.1; 95% CI, 1.1–8.8; P = .03).
- Allergist referrals/testing: 36% in intervention vs 10% in control.
Lead author Ruchi Gupta, MD, MPH, professor of pediatrics and medicine at Northwestern University Feinberg School of Medicine and pediatrician at Lurie Children’s, emphasized the importance of structural supports for busy practices:
“We found that supporting pediatricians with training, electronic health record prompts and educational materials for parents significantly improved their ability to counsel families on early peanut introduction,” said Gupta.
She added, “Because pediatric visits at 4 and 6 months are so busy, this support is critical to ensure families receive clear guidance. Our hope is that these conversations will help parents feel confident introducing peanut products early. We want to reverse the trend of increasing food allergies in the United States through prevention.”
Lucy Bilaver, PhD, associate professor of pediatrics at Feinberg and lead statistician for the study, highlighted the use of EHR data. “We were able to measure the primary outcome by making use of the clinical notes and structured data that pediatric clinicians generate during these well-child visits,” she said.
Implications for practice
The findings demonstrate that simple, low-cost interventions can meaningfully improve clinician adherence to evidence-based allergy prevention guidelines.
Implementing standardized prompts within the EHR and providing clear educational materials for families can enhance pediatrician counseling and support timely peanut introduction. These approaches may be especially valuable in busy practice settings where preventive discussions are often condensed.
According to Gupta, “While more work is needed, the success of this intervention supports wider dissemination to prevent peanut allergy in children.”
Long-term outcomes from the iREACH Trial will be tracked until participating children reach 2.5 years of age to determine whether increased clinician adherence results in lower rates of peanut allergy.